A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
Price : $35 *
At a glance
- Drugs Filgrastim (Primary) ; Plerixafor
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 21 Dec 2016 Status changed from active, no longer recruiting to completed.
- 14 Jun 2016 Status changed from recruiting to active, no longer recruiting.